Table 2.

List of nanocarriers/NPs for the delivery of potential therapeutic miRNAs for UM.

Potential Therapeutic miRNA for UM	Nanocarriers/NPs	Targeting Cells	Ref.
Anti-miR-21 oligonucleotide	Aptamer-decorated PEGylated PLGA NPs	Ovarian cancers	[104]
	Acid-triggered charge-reversible graphene-based multilayer polymers	Triple-negative breast cancer	[105]
	GNPs	Breast cancer cells	[106]
	Chlorotoxin-coupled stable nucleic acid lipid NPs	Glioblastoma	[107]
	3WJ-based RNA NPs	Glioblastoma	[108]
Let-7b	HA-G5 PAMAM dendrimer	CD44+ non-small-cell lung cancer cells	[109]
	Cationic liposomes	Neuroblastoma	[110]
miR-17	DOTAP-modified PLGA lipid–polymer hybrid NPs	Bronchial epithelial cells	[111]
miR-124a	Disulfide-linked PEI NPs	Neuron cells	[86]
miR-142-3p	G5 PAMAM dendrimers	Myeloid cells	[112]
miR-145	Micelles	Vascular smooth muscle cells	[113]
	Disulfide cross-linked micelles	Colon cancer cells	[114]
	Nanocapsules	Colorectal cancer cells	[115]
	PLGA NPs	Vascular smooth muscle cells	[116]
	Chitosan-thiolated dextran NPs	Cancer cells	[117,118]
	Magnetic nanoformulation	Pancreatic cancer	[119]
	Polyarginine-disulfide-linked PEI NPs	Prostate cancer	[120]
	GNPs	Prostate and breast cancer cells	[121]
	HA-PLGA/PEI with miR-145 expression plasmid	Colon carcinoma	[122]
	Chitosan polyplex NPs with miR-145 expression plasmid	MCF-7	[123]
miR-182	PEGylated GNP nanogel	Metastatic breast cancer	[124]
	PEGylated GNPs	Glioblastoma	[125]
miR-34a, miR-137, miR-144 and miR-182	GNPs	UM cells	[126]